JP2009100745A5 - - Google Patents

Download PDF

Info

Publication number
JP2009100745A5
JP2009100745A5 JP2008292842A JP2008292842A JP2009100745A5 JP 2009100745 A5 JP2009100745 A5 JP 2009100745A5 JP 2008292842 A JP2008292842 A JP 2008292842A JP 2008292842 A JP2008292842 A JP 2008292842A JP 2009100745 A5 JP2009100745 A5 JP 2009100745A5
Authority
JP
Japan
Prior art keywords
active fragment
isolated antibody
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008292842A
Other languages
English (en)
Japanese (ja)
Other versions
JP5384912B2 (ja
JP2009100745A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009100745A publication Critical patent/JP2009100745A/ja
Publication of JP2009100745A5 publication Critical patent/JP2009100745A5/ja
Application granted granted Critical
Publication of JP5384912B2 publication Critical patent/JP5384912B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008292842A 2001-05-11 2008-11-14 特異的結合タンパク質およびその使用 Expired - Lifetime JP5384912B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29041001P 2001-05-11 2001-05-11
US60/290,410 2001-05-11
US32601901P 2001-09-28 2001-09-28
US60/326,019 2001-09-28
US34225801P 2001-12-21 2001-12-21
US60/342,258 2001-12-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002589639A Division JP4414142B2 (ja) 2001-05-11 2002-05-13 特異的結合タンパク質およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013172146A Division JP6082673B2 (ja) 2001-05-11 2013-08-22 特異的結合タンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2009100745A JP2009100745A (ja) 2009-05-14
JP2009100745A5 true JP2009100745A5 (OSRAM) 2010-01-21
JP5384912B2 JP5384912B2 (ja) 2014-01-08

Family

ID=27403978

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2002589639A Expired - Lifetime JP4414142B2 (ja) 2001-05-11 2002-05-13 特異的結合タンパク質およびその使用
JP2007177834A Withdrawn JP2007306933A (ja) 2001-05-11 2007-07-05 特異的結合タンパク質およびその使用
JP2008292842A Expired - Lifetime JP5384912B2 (ja) 2001-05-11 2008-11-14 特異的結合タンパク質およびその使用
JP2013172146A Expired - Lifetime JP6082673B2 (ja) 2001-05-11 2013-08-22 特異的結合タンパク質およびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2002589639A Expired - Lifetime JP4414142B2 (ja) 2001-05-11 2002-05-13 特異的結合タンパク質およびその使用
JP2007177834A Withdrawn JP2007306933A (ja) 2001-05-11 2007-07-05 特異的結合タンパク質およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013172146A Expired - Lifetime JP6082673B2 (ja) 2001-05-11 2013-08-22 特異的結合タンパク質およびその使用

Country Status (12)

Country Link
US (3) US7589180B2 (OSRAM)
EP (3) EP2163256B1 (OSRAM)
JP (4) JP4414142B2 (OSRAM)
AT (1) ATE446317T1 (OSRAM)
AU (1) AU2002311919B8 (OSRAM)
CA (1) CA2447139C (OSRAM)
CY (1) CY1109725T1 (OSRAM)
DE (1) DE60234094D1 (OSRAM)
DK (2) DK2163256T3 (OSRAM)
ES (2) ES2334494T5 (OSRAM)
PT (2) PT1392359E (OSRAM)
WO (1) WO2002092771A2 (OSRAM)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794494B1 (en) * 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2163256B1 (en) * 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
AU2003286002B2 (en) * 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ATE517922T1 (de) * 2002-11-08 2011-08-15 Ablynx Nv Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
JP2006519763A (ja) * 2002-11-08 2006-08-31 アブリンクス エン.ヴェー. 治療用ポリペプチドの投与法およびそのためのポリペプチド
WO2004067029A1 (fr) * 2002-12-27 2004-08-12 Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. Procede de preparation d'un vaccin et vaccins antitumoraux
KR20050116392A (ko) * 2003-03-24 2005-12-12 지모제넥틱스, 인코포레이티드 항-il-22ra 항체 및 결합 파트너 및 염증에 있어서의사용 방법
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
PT1871805T (pt) * 2005-02-07 2019-12-02 Roche Glycart Ag Moléculas de ligação a antigénios que se ligam ao rfce, vetores que as codificam e as suas utilizações
KR20070120559A (ko) * 2005-03-29 2007-12-24 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 새로운 모낭 생성 방법, 탈모 치료 방법 및 체모 제거 방법
JP2006284330A (ja) * 2005-03-31 2006-10-19 Gunma Univ アシアロgm1の免疫学的測定キット並びに抗アシアロgm1抗体の免疫学的測定キット
US20090155272A1 (en) * 2005-09-30 2009-06-18 Muschler John L Targeted pharmaceuticals and ligands
CA2643144A1 (en) * 2006-02-24 2007-08-30 Arius Research, Inc. Cancerous disease modifying antibody 141205-04
US20090280503A1 (en) * 2006-09-15 2009-11-12 James Fiore Method for detecting and treating skin disorders
US8252749B2 (en) 2006-09-28 2012-08-28 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair
MX338185B (es) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
CN104151430A (zh) 2007-03-01 2014-11-19 西福根有限公司 重组抗表皮生长因子受体抗体组合物
EP2134854B1 (en) 2007-03-15 2015-04-15 Ludwig Institute for Cancer Research Ltd. Treatment method using egfr antibodies and src inhibitors and related formulations
US8900816B2 (en) * 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
WO2009023265A1 (en) * 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
UY31504A1 (es) 2007-11-30 2009-07-17 Construcciones de union de antigenos
EP2331577B1 (en) 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
CN102574924A (zh) * 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
WO2011035465A1 (zh) * 2009-09-22 2011-03-31 上海市肿瘤研究所 特异性结合蛋白及其使用
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
JP2011144124A (ja) * 2010-01-13 2011-07-28 Fujirebio Inc 活性型egfr特異抗体
NZ602084A (en) 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
EP2808344A1 (en) 2010-06-01 2014-12-03 Monash University Antibodies directed to the receptor tyrosine kinase c-Met
WO2012058592A2 (en) * 2010-10-29 2012-05-03 Immunogen, Inc. Non-antagonistic egfr-binding molecules and immunoconjugates thereof
CA2815277A1 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ,インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
ES2605493T3 (es) 2010-12-23 2017-03-14 F. Hoffmann-La Roche Ag Detección de un polipéptido modificado post-traduccionalmente mediante un agente ligante bivalente
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012100346A1 (en) 2011-01-24 2012-08-02 Ym Biosciences Inc. Antibodies selective for cells presenting egfr at high density
CA2833477A1 (en) 2011-04-21 2012-10-26 Seattle Genetics, Inc. Novel binder-drug conjugates (adcs) and their use
MX2014006087A (es) 2011-11-21 2014-08-01 Immunogen Inc Metodo de tratamiento de tumores que son resistentes a terapias contra el receptor del factor de crecimiento epidermico (egfr) con agentes citotoxicos conjugados con anticuerpos dirigidos contra el receptor del factor de crecimiento epidermico.
CN103382223B (zh) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
EP2922872B1 (en) 2012-11-21 2018-10-10 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
EP2970491A4 (en) * 2013-03-15 2016-11-23 Alper Biotech Llc MONOCLONAL ANTIBODIES AGAINST EGFR AND USES THEREOF
EP3016980B1 (en) 2013-07-05 2020-05-06 Formation Biologics Inc. Egfr antibody conjugates
HK1226081A1 (zh) 2013-09-12 2017-09-22 Halozyme, Inc. 修饰的抗表皮生长因子受体抗体及其使用方法
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
WO2015092394A1 (en) * 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
KR102399005B1 (ko) 2014-03-11 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 항-egfrviii 항체 및 그것의 용도
CA2942101A1 (en) 2014-03-21 2015-09-24 Abbvie Inc. Anti-egfr antibodies and antibody drug conjugates
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
RU2721271C2 (ru) 2014-10-23 2020-05-18 Иннейт Фарма Лечение раковых заболеваний с применением анти-nkg2a средств
JP6616833B2 (ja) * 2014-11-25 2019-12-04 ファームアブシン インコーポレイテッド 新規EGFRvIII抗体及びこれを含む組成物
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体(adc)および抗体プロドラッグ複合体(apdc)
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
US11660351B2 (en) 2016-12-21 2023-05-30 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN116948035A (zh) * 2017-06-25 2023-10-27 西雅图免疫公司 多特异性抗体及其制备和使用方法
US10386338B2 (en) 2017-10-30 2019-08-20 Cynthia Rena Wright DNA/RNA PEMS microcantilever probe for detection of viral infection and detection of genetic variants
WO2020136147A1 (en) 2018-12-26 2020-07-02 Innate Pharma Compounds and methods for treatment of head and neck cancer
AU2020249296A1 (en) * 2019-03-27 2021-11-11 National Research Council Of Canada Anti-EGFRvIII antibodies and antigen-binding fragments thereof
WO2021041725A1 (en) * 2019-08-27 2021-03-04 The Trustees Of The Univeristy Of Pennsylvania SYNTHETIC CARS TO TREAT IL13Rα2 POSITIVE HUMAN AND CANINE TUMORS
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
AU2021230226B2 (en) 2020-03-06 2025-06-26 Daiichi Sankyo Company, Limited Antibody-drug conjugate including novel cyclic dinucleotide derivative
WO2022068870A1 (zh) 2020-09-30 2022-04-07 中国科学院动物研究所 靶向egfr的嵌合抗原受体
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體-免疫賦活化劑共軛物之新穎製造方法
US20240279364A1 (en) 2021-03-12 2024-08-22 Daiichi Sankyo Company, Limited Glycan, and method for producing medicine containing glycan
EP4359440A1 (en) 2021-06-22 2024-05-01 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof
JPWO2023167238A1 (OSRAM) 2022-03-02 2023-09-07
AU2023336004A1 (en) 2022-08-29 2025-03-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate including mutant fc region
EP4585601A1 (en) 2022-09-09 2025-07-16 Daiichi Sankyo Company, Limited Novel oligosaccharide, production intermediate for novel oligosaccharide, production method for novel oligosaccharide, and production method for production intermediate for novel oligosaccharide

Family Cites Families (286)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
USRE31006E (en) 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4162940A (en) 1977-03-31 1979-07-31 Takeda Chemical Industries, Ltd. Method for producing Antibiotic C-15003 by culturing nocardia
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4263294A (en) 1978-11-20 1981-04-21 Takeda Chemical Industries, Ltd. Maytansinoids, pharmaceutical compositions thereof and method of use thereof
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5622790A (en) 1979-07-31 1981-03-03 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
EP0043718B1 (en) 1980-07-07 1984-11-28 National Research Development Corporation Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4413132A (en) 1980-11-18 1983-11-01 The Upjohn Company Antibiotic CC-1065 indoline intermediates
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2523445A1 (fr) 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
US4418064A (en) 1982-09-29 1983-11-29 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
WO1985003357A1 (en) 1984-01-30 1985-08-01 Icrf Patents Ltd. Improvements relating to growth factors
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5851526A (en) 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
IN165717B (OSRAM) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5034223A (en) 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5047324A (en) 1986-12-09 1991-09-10 Miles Inc. Substantially pure enzyme-antibody conjugate preparations
US5332837A (en) 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US4937183A (en) 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
EP0329184A3 (en) 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
KR0137959B1 (ko) 1988-09-12 1998-05-15 로버트 에이. 아미테이지 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5171563A (en) 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
JPH04501266A (ja) 1988-10-12 1992-03-05 セントコアー,インコーポレーテッド ヨード―125で標識された放射線療法用接合体
CA2006408A1 (en) 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
US5013547A (en) 1989-02-07 1991-05-07 Erbamont, Inc. Anticancer drug - antibody conjugates and method for preparing same
US5980896A (en) 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
WO1991003489A1 (en) * 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
EP0515527A4 (en) 1990-02-20 1993-08-25 Coulter Corporation Improved antibody-enzyme direct conjugates and method of making same
WO1991016350A1 (en) 1990-04-20 1991-10-31 Ludwig Institute For Cancer Research Aberrant, epidermal growth factor receptor dna, rna and protein forms and method
CA2078118C (en) 1990-04-25 1999-11-16 Paul A. Aristoff Cc-1065 analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6248332B1 (en) 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
FI101678B1 (fi) 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
WO1992015683A1 (en) 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
TW205553B (OSRAM) * 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
US6797492B2 (en) * 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
DK0586002T3 (da) 1992-08-18 2000-06-19 Centro Inmunologia Molecular Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
WO1995024220A1 (en) 1994-03-07 1995-09-14 Medarex, Inc. Bispecific molecules having clinical utilities
RU2170257C2 (ru) 1994-03-17 2001-07-10 Мерк Патент Гмбх Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US5911995A (en) 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
ATE262586T1 (de) 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US6548530B1 (en) 1995-10-03 2003-04-15 The Scripps Research Institute CBI analogs of CC-1065 and the duocarmycins
US6699715B1 (en) 1995-11-30 2004-03-02 Bristol-Myers Squibb Co. Modified sFv molecules which mediate adhesion between cells and uses thereof
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
US5708156A (en) * 1996-05-31 1998-01-13 Ilekis; John V. Epidermal growth factor receptor-like gene product and its uses
US6060608A (en) 1996-05-31 2000-05-09 The Scripps Research Institute Analogs of CC-1065 and the duocarmycins
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998052925A1 (en) 1997-05-22 1998-11-26 The Scripps Research Institute Analogs of duocarmycin and cc-1065
AU9102398A (en) * 1997-09-12 1999-04-05 Lumigen, Inc. Novel compounds for generating chemiluminescence with a peroxidase
NZ503966A (en) 1997-10-14 2002-10-25 Scripps Research Inst iso -CBI and iso -CI analogs of CC-1065 and the duocarmycins
EP1037865A4 (en) 1997-12-08 2004-03-31 Scripps Research Inst SYNTHESIS OF CC-1065 / DUOCARMYCIN ANALOGS
US6464686B1 (en) 1998-01-21 2002-10-15 Abbott Laboratories Polyurethane feeding tube and associated adaptors
TR200002271T2 (tr) * 1998-02-06 2000-11-21 Ilexus Pty Limited Fc alıcılarının üç boyutlu yapıları ve modelleri ve bunların kullanımı
US7553809B2 (en) * 1998-02-06 2009-06-30 Ilexus Pty Limited Fc receptor modulators and uses thereof
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20030224001A1 (en) 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
EP1073464B1 (en) 1998-04-28 2004-10-06 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
AUPP380498A0 (en) * 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US20030215387A1 (en) 1998-09-04 2003-11-20 Peter Harrison Bifunctional antibodies and their use in targeting anti-tumour agents
AU769489B2 (en) * 1998-09-11 2004-01-29 Ilexus Pty Limited Fc receptor modulators and uses thereof
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
SK16522001A3 (sk) 1999-05-14 2002-10-08 Imclone Systems Incorporated Liečivo na inhibíciu rastu refraktérnych nádorov
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
HUP0204142A3 (en) 2000-02-25 2004-12-28 Univ Durham Anti-egfrviii scfv-antibodies with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
CA2408175A1 (en) 2000-03-10 2001-09-20 Thomas Jefferson University Sensitive detection of wild-type and mutant egfr by specific elisa assays in any biological sample
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US6596302B2 (en) 2000-04-13 2003-07-22 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
DE50104114D1 (de) 2000-05-02 2004-11-18 Tietze Lutz F Neue prodrugs von 6-hydroxy-2,3-dihydro-1h-indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo 3,2-e]indolen und 5-hydroxy-1,2-dihydro-3h-benzo e]indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro-benzo f]chinolin-derivaten für eine selektive krebstherapie
EP1282443B1 (en) 2000-05-19 2009-09-02 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
AUPQ841800A0 (en) 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
JP2004527456A (ja) 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Egf受容体拮抗剤による過増殖性の疾患の治療
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AR030612A1 (es) 2000-09-12 2003-08-27 Smithkline Beecham Corp Procedimiento e intermedios
EP1320522B8 (en) 2000-09-19 2006-02-01 Moses Lee Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins
DE10048417A1 (de) 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker
JP2004511479A (ja) * 2000-10-13 2004-04-15 アストラゼネカ アクチボラグ キナゾリン誘導体
EP1361893B1 (en) 2001-02-19 2012-10-24 Merck Patent GmbH Modified anti-egfr antibodies with reduced immunogenicity
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20020156274A1 (en) 2001-03-16 2002-10-24 Terfloth Gerald J. Process for preparing maytansinol
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
RU2003134180A (ru) 2001-05-08 2005-02-10 Мерк Патент ГмбХ (DE) Комбинированная терапия, использующая антитела к egfr и антигормональные средства
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2163256B1 (en) 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CN1463270A (zh) 2001-05-31 2003-12-24 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
BRPI0210405B8 (pt) 2001-06-13 2021-05-25 Genmab As anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003014159A1 (en) 2001-08-03 2003-02-20 Commonwealth Scientific And Industrial Research Organisation Methods of screening based on the egf receptor crystal structure
DE10138876B4 (de) 2001-08-08 2008-11-06 Forschungszentrum Jülich GmbH Genetisch modifizierte zyklisch-Nukleotid-gesteuerte lonenkanäle und deren Verwendung
CA2459308A1 (en) 2001-09-07 2003-03-20 Dale L. Boger Cbi analogues of cc-1065 and the duocarmycins
US20030109682A1 (en) 2001-09-07 2003-06-12 Daniel Santi Maytansines and maytansine conjugates
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1458737A4 (en) 2001-11-21 2006-03-29 Univ Washington BIOSYNTHETIC MULTIGENIC FAMILY FOR ANTI-TUMOR AGENT ANSAMITOCIN MAYTANSINOIDE
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
JP2005532258A (ja) 2002-01-03 2005-10-27 スミスクライン・ビーチャム・コーポレイション 免疫コンジュゲートの調製方法
US6790954B2 (en) 2002-01-29 2004-09-14 Immunogen, Inc. Mutant Actinosynnema pretiosum strain with increased maytansinoid production
EP1490109A4 (en) 2002-03-19 2006-04-19 Penn State Res Found EGFR LIGANDS AND APPLICATION PROCEDURES
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
JP2005525423A (ja) 2002-05-13 2005-08-25 スミスクライン・ビーチャム・コーポレイション メイタンシノールの調製方法
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
WO2005056606A2 (en) 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
WO2003101491A1 (en) 2002-06-03 2003-12-11 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
MXPA05001390A (es) 2002-08-02 2005-07-29 Immunogen Inc Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico.
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
ES2361739T3 (es) 2002-08-16 2011-06-21 Immunogen, Inc. Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña.
KR20050048615A (ko) 2002-08-19 2005-05-24 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
MXPA05003796A (es) 2002-10-10 2006-02-22 Merck Patent Gmbh Anticuerpos anti-erb-b biespecificos y su uso en terapia de tumor.
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US20040147428A1 (en) 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
EP1622941A2 (en) 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
WO2004101767A2 (en) 2003-05-13 2004-11-25 The Scripps Research Institute Cbi analogues of the duocarmycins and cc-1065
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CN104059147A (zh) 2003-06-27 2014-09-24 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
CN1922210A (zh) 2003-12-19 2007-02-28 健泰科生物技术公司 可用作治疗剂的单价抗体片段
US20050214310A1 (en) 2004-01-23 2005-09-29 Seattle Genetics, Inc. Melphalan prodrugs
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AU2005218642B2 (en) 2004-03-02 2011-04-28 Seagen Inc. Partially loaded antibodies and methods of their conjugation
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
EP1733056B1 (en) 2004-03-31 2013-05-22 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
WO2005099754A2 (en) 2004-04-14 2005-10-27 The Ohio State University Research Foundation Maytansinoid analogs as antitumor agents
MXPA06013413A (es) 2004-05-19 2007-01-23 Medarex Inc Enlazadores quimicos y conjugados de los mismos.
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
EP3042964A1 (en) 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
US20060029574A1 (en) * 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
EP1688415A1 (en) 2004-12-07 2006-08-09 Aventis Pharma S.A. Cytotoxic agents comprising new C-2 modified taxanes
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
WO2006063042A2 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
BRPI0609615A2 (pt) 2005-04-01 2010-04-27 Amgen Inc métodos de predição da eficácia de tratamento de agente de ligação especìfica a egfr em tratamento de cáncer relacionado com egfr num sujeito, de tratamento do mesmo e de determinação da eficácia de tratamento em paciente
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
ES2585357T3 (es) 2005-07-07 2016-10-05 Seattle Genetics, Inc. Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
SI3248613T1 (sl) 2005-07-18 2022-04-29 Seagen Inc. Konjugati beta-glukuronidni linker-zdravilo
BRPI0614100A2 (pt) 2005-08-03 2011-03-09 Immunogen Inc formulações de imunoconjugado lìquidas
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
CA2617953C (en) 2005-08-09 2013-12-17 Millennium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
IL282138B2 (en) 2005-08-24 2024-01-01 Immunogen Inc Process for preparing purified drug conjugates
ES2283192B1 (es) 2005-09-16 2008-09-16 GAMESA INNOVATION & TECHNOLOGY, S.L. Metodo de montaje de elementos en el interior de la torre de un aerogenerador.
ES2416136T3 (es) 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
ES2375843T3 (es) 2005-10-26 2012-03-06 Medarex, Inc. Procedimientos y compuestos para la preparación de an�?logos de cc-1065.
PL1945647T3 (pl) 2005-11-08 2012-04-30 Immunogen Inc Procesy wytwarzania maytansinolu
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
PL1948180T3 (pl) 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
ES2340205T3 (es) 2005-11-12 2010-05-31 Eli Lilly And Company Anticuerpos anti-egfr.
CA2636074A1 (en) 2006-01-04 2007-07-12 University Of Montpellier 1 Combination therapy using anti-egfr and anti-her2 antibodies
JP5346589B2 (ja) 2006-02-02 2013-11-20 シンタルガ・ビーブイ 水溶性cc−1065類似体及びその接合体
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
US20090280503A1 (en) 2006-09-15 2009-11-12 James Fiore Method for detecting and treating skin disorders
WO2008058021A2 (en) 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
US7790164B2 (en) 2006-11-14 2010-09-07 Van Andel Research Institute Fragments of antibodies to epidermal growth factor receptor and methods of their use
AU2007353412A1 (en) 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
MX338185B (es) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
EP2134854B1 (en) 2007-03-15 2015-04-15 Ludwig Institute for Cancer Research Ltd. Treatment method using egfr antibodies and src inhibitors and related formulations
WO2008154927A1 (en) 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
US8680293B2 (en) 2007-08-01 2014-03-25 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
WO2009023265A1 (en) 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
US20090269343A1 (en) 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
CN104524590B (zh) 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3100745B1 (en) 2009-02-05 2018-04-18 Immunogen, Inc. Novel benzodiazepine derivatives
MX2011011670A (es) 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
WO2011035465A1 (zh) 2009-09-22 2011-03-31 上海市肿瘤研究所 特异性结合蛋白及其使用
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Similar Documents

Publication Publication Date Title
JP2009100745A5 (OSRAM)
US11390667B2 (en) Compositions and methods for the treatment of neuromyelitis optica
AU2020200980B2 (en) Oncostatin M receptor antigen binding proteins
JP2004531263A5 (OSRAM)
JP6443870B2 (ja) ヒトpac1抗体
CN120131936A (zh) 用于治疗癌症的dll3/cd3结合蛋白
CN107001480B (zh) 用于人c-maf的结合成员
CA2793647A1 (en) Prophylaxis of colorectal and gastrointestinal cancer
KR20150013935A (ko) 트랜스포터에 대한 항체 및 이의 용도
JP2014515600A5 (OSRAM)
CN116249547B (zh) 脑特异性血管生成抑制剂1(bai1)抗体及其用途
EP3746477A1 (en) Compounds that modulate the interaction of vista and vsig3 and methods of making and using
JP2021518748A (ja) カルシトニン遺伝子関連ペプチド(cgrp)アンタゴニスト抗体
CN116444672B (zh) 人表皮生长因子3的抗体、其制备方法及其应用
US10030076B2 (en) Antibodies against glioma biomarkers
CN117343185A (zh) 一种抗犬pd-1抗体及其用途
KR20210122813A (ko) 항체 및 그의 기능성 단편
CN115785269B (zh) 抗pd-l1的抗体及其应用
Doiron Rational Design of Selective Protein Therapeutics for Structurally and Functionally Complex Targets
US12378307B2 (en) Antibodies blocking DLL4-mediated notch signalling
JP2019026625A (ja) 抗イヌcd20モノクローナル抗体
KR20210090172A (ko) Epn1을 표적화하는 항체
NZ777568A (en) Bispecific antibody binding to tfr